ZVSA — Zyversa Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.21m
- $0.68m
Annual cashflow statement for Zyversa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.7 | -8.08 | -14.1 | -98.3 | -9.41 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4.45 | 4.02 | 4.31 | 96.4 | 0.91 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.11 | -1.02 | 5.66 | 2.6 | 0.93 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -5.11 | -5.08 | -4.89 | -8.72 | -7.56 |
| Financing Cash Flow Items | -0.142 | 0 | -0.099 | -2.42 | -0.588 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.56 | 5.23 | 1.87 | 5.96 | 5.95 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.55 | 0.154 | -3.02 | -2.76 | -1.61 |